Insulin-Like Growth Factor 1 Receptor as a Therapeutic Target in Ewing Sarcoma: Lack of Consistent Upregulation or Recurrent Mutation and a Review of the Clinical Trial Literature

<table>Gating of cells for flow cytometric analysis of IGF-1R surface expression in TC71 and NWTb3 cells stained with Aldefluor. Top: Aldefluor alone without IGF-IR-PE antibody. Bottom: Aldefluor plus IGF-1R-PE antibody.</table>

Sarcoma

fig3

Figure 3

Figure 3: Insulin-Like Growth Factor 1 Receptor as a Therapeutic Target in Ewing Sarcoma: Lack of Consistent Upregulation or Recurrent Mutation and a Review of the Clinical Trial Literature 

Figure 3 | Insulin-Like Growth Factor 1 Receptor as a Therapeutic Target in Ewing Sarcoma: Lack of Consistent Upregulation or Recurrent Mutation and a Review of the Clinical Trial Literature 